Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Apr;35(4):524-537.
doi: 10.1080/09540121.2022.2159312. Epub 2023 Feb 1.

Providing HIV pre-exposure prophylaxis to men who have sex with men and transgender women in hospitals and community-led clinics in Thailand: acceptance, patterns of use, trends in risk behaviors, and HIV incidence

Cheewanan L  1 , Chomnad M  2 , Nittaya P  3 , Deondara T  3 , Thana K  4 , Tharee P  5 , Supabhorn P  3 , Patcharaporn P  1 , Prin V  2 , Surang J  6 , Danai L  7 , Thitiyanun N  8 , Nuchapong J  2 , Michael M  9
Affiliations

Providing HIV pre-exposure prophylaxis to men who have sex with men and transgender women in hospitals and community-led clinics in Thailand: acceptance, patterns of use, trends in risk behaviors, and HIV incidence

Cheewanan L et al. AIDS Care. 2023 Apr.

Abstract

From May 2015 to June 2018, we conducted a PrEP demonstration project at two hospitals and four community-led clinics in Bangkok and Pattaya. HIV-negative, MSM and TGW aged ≥18 years old, reporting sex without a condom, were offered daily PrEP. Participants received HIV testing and completed a computer-based questionnaire at enrollment, 6 and 12 months. We collected self-reported PrEP adherence at months 1, 3, 6, 9, and 12. We used logistic regression to determine factors associated with the decision to take PrEP and calculated HIV incidence among baseline HIV-negative participants. Of 803 participants enrolled, 349 (43.5%) started PrEP. Participants were more likely to start PrEP if they were sex workers, had moderate or high self-perceived risk of HIV, or a high PrEP-knowledge score. Participants used PrEP for a median of 6.1 months. Reported condom use increased and the number of sex partners decreased during follow-up regardless of PrEP use. Six participants not-taking PrEP acquired HIV (HIV incidence 2.2 per 100 person-years), and five taking PrEP acquired HIV (HIV incidence 2.1 per 100 person-years). All five reported taking <4 pills the weeks before study visits.

Keywords: HIV incidence; MSM; Pre-exposure prophylaxis; Thailand; transgender women.

PubMed Disclaimer

Conflict of interest statement

Competing interests

The authors declared no competing interests.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Figures

Figure 1.
Figure 1.
Enrollment and follow up in the HIV pre-exposure prophylaxis (PrEP) project, Thailand 2015–2018.
Figure 2.
Figure 2.
Participant retention and adherence to pre-exposure prophylaxis (PrEP) through 12 months in the PrEP project, Thailand 2015–2018.
See this image and copyright information in PMC

References

    1. Adams JL, Shelley K, & Nicol MR (2019). Review of real-world implementation data on emtricitabine-tenofovir disoproxil fumarate as HIV Pre-exposure prophylaxis in the United States. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 39(4), 486–500. 10.1002/phar.2240 - DOI - PMC - PubMed
    1. Anderson PL, Glidden DV, Liu A, Buchbinder S, Lama JR, Guanira JV, McMahan V, Bushman LR, Casapia M, Montoya-Herrera O, Veloso VG, Mayer KH, Chariyalertsak S, Schechter M, Bekker LG, Kallas EG, & Grant RM & iPrEx Study, T (2012). Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Science Translational Medicine, 4(151), 151ra125. 10.1126/scitranslmed.3004006 - DOI - PMC - PubMed
    1. Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, Tappero JW, Bukusi EA, Cohen CR, Katabira E, Ronald A, Tumwesigye E, Were E, Fife KH, Kiarie J, Farquhar C, John-Stewart G, Kakia A, Odoyo J, … PartnersPrE. P. S. T. (2012). Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. New England Journal of Medicine, 367(5), 399–410. 10.1056/NEJMoa1108524 - DOI - PMC - PubMed
    1. Bavinton BR, & Grulich AE (2021). HIV pre-exposure prophylaxis: Scaling up for impact now and in the future. The Lancet Public Health, 6(7), e528–e533. 10.1016/S2468-2667(21)00112-2 - DOI - PubMed
    1. Blumenthal J, & Haubrich RH (2014). Will risk compensation accompany pre-exposure prophylaxis for HIV? AMA Journal of Ethics, 16(11), 909–915. 10.1001/virtualmentor.2014.16.11.stas1-1411 - DOI - PMC - PubMed

Publication types

Substances